Howland Robert H
University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, USA.
J Psychosoc Nurs Ment Health Serv. 2008 Aug;46(8):19-22. doi: 10.3928/02793695-20080801-05.
This article reviews the unique prodrug stimulant lisdexamfetamine dimesylate (LDX, Vyvanse), an approved treatment for attention-deficit/hyperactivity disorder. LDX is an inactive prodrug in which l-lysine is chemically bonded to d-amphetamine. Although its efficacy is not significantly different from that of other stimulants, LDX may be different with respect to potential toxicity and abuse liability. In this article, I will review the short-term controlled studies that were the basis for LDX's approval for both children and adults; the lack of and need for more long-term studies; two double-blind, placebo-controlled, crossover studies that examined LDX's abuse liability; and clinical uses for the drug. The clinical implications stemming from LDX's unique characteristics are also discussed.
本文综述了独特的前体药物刺激性药物二甲磺酸赖右苯丙胺（LDX，商品名：维思通），它是一种已获批准用于治疗注意力缺陷多动障碍的药物。LDX是一种无活性的前体药物，其中L-赖氨酸与d-苯丙胺通过化学键相连。尽管其疗效与其他刺激性药物相比并无显著差异，但LDX在潜在毒性和滥用可能性方面可能有所不同。在本文中，我将回顾作为LDX获批用于儿童和成人依据的短期对照研究；长期研究的缺乏及开展更多此类研究的必要性；两项检验LDX滥用可能性的双盲、安慰剂对照交叉研究；以及该药物的临床应用。还将讨论源于LDX独特特性的临床意义。
